Know Cancer

forgot password

Cost-Effectiveness of Follow-up of Patients With Superficial Bladder Cancer

Phase 4
Open (Enrolling)
Bladder Cancer

Thank you

Trial Information

Cost-Effectiveness of Follow-up of Patients With Superficial Bladder Cancer

The randomized clinical study consists of two intervention arms. The control arm consists of
a conventional follow-up based on regular monitoring for urinary bladder UCC recurrences by
cystoscopy. In the test arm a proportion of the cystoscopies is replaced by microsatellite
analysis on voided urine. Both arms will be stratified for clinical and pathological tumour
parameters as well as for the mutation status of the prognostic FGFR3 gene mutation.

Inclusion Criteria:

- All patients with resectable pT1 or pTa, grade G1-G2 transitional cell carcinoma of
the bladder which is biopsy proven

Exclusion Criteria:

- Patients who present or presented with a transitional cell carcinoma of the bladder,
stage pT2 or more invasive, or carcinoma in situ (CIS) and/or G3 diagnosed in history

Type of Study:


Study Design:

Time Perspective: Prospective

Principal Investigator

Th. van der Kwast, Prof PhD MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Erasmus MC, JNI


Netherlands: Independent Ethics Committee

Study ID:

*ZON-MW 945-02-046*



Start Date:

July 2002

Completion Date:

July 2005

Related Keywords:

  • Bladder Cancer
  • superficial urothelial cell carcinoma
  • urinary analysis
  • Loss of heterozygosity
  • FGFR3 mutation
  • follow-up
  • Urinary Bladder Neoplasms